GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes

Diabetes

Volumn 60, Issue 4, 2011, Pages 1270-1276

  Mentis, Nikolaos ^a   Vardarli, Irfan ^a   Köthe, Lars D ^a   Holst, Jens J ^b   Deacon, Carolyn F ^b   Theodorakis, Michael ^c   Meier, Juris J ^d   Nauck, Michael A ^a  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE PLUS METFORMIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN TREATMENT; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED;

EID: 79953165707     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1332     Document Type: Article

References (54)

1. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52 (Pubitemid 16162741)
2. Nauck MA, Baller B, Meier JJ. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 2004;53(Suppl. 3):S190-S196 (Pubitemid 39564543)
3. Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 2007;56:1951-1959
4. Knop FK, Vilsbøll T, Højberg PV, et al. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Regul Pept 2007;144:123-130 (Pubitemid 350030308)
5. Krarup T, Saurbrey N, Moody AJ, Kühl C, Madsbad S. Effect of porcine gastric inhibitory polypeptide on b-cell function in type I and type II diabetes mellitus. Metabolism 1987;36:677-682 (Pubitemid 17100983)
6. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91:301-307 (Pubitemid 23037285)
7. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002;45:1111-1119 (Pubitemid 34985287)
8. Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007;56:1551-1558 (Pubitemid 46842610)
9. Younan SM, Rashed LA. Impairment of the insulinotropic effect of gastric inhibitory polypeptide (GIP) in obese and diabetic rats is related to the down-regulation of its pancreatic receptors. Gen Physiol Biophys 2007;26:181-193 (Pubitemid 350186529)
10. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744
11. Nauck MA, Meier JJ. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 2005;128:135-148 (Pubitemid 40380914)
12. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3853-3860 (Pubitemid 32755988)
13. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 1997;40:205-211 (Pubitemid 27060294)
14. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705 (Pubitemid 46048557)
15. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch 1998;435:583-594 (Pubitemid 28098639)
16. Flatt PR. Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes? Diabet Med 2008;25:759-764
17. Gault VA, Irwin N, Harriott P, Flatt PR, O'Harte FP. DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP. Cell Biol Int 2003;27:41-46
18. Gault VA, O'Harte FP, Flatt PR. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 2003;37:253-263
19. Irwin N, Gault VA, Green BD, et al. Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37). Biol Chem 2005;386:679-687
20. Irwin N, Green BD, Gault VA, et al. Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice. Peptides 2006;27:893-900
21. Parker JC, Irwin N, Lavery KS, et al. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin (9-39)amide in obese diabetic (ob/ob) mice. Biol Chem 2007;388:221-226
22. Irwin N, O'Harte FP, Gault VA, et al. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential. J Med Chem 2006;49:1047-1054
23. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocr Rev 1988;9:122-134
24. Aaboe K, Knop FK, Vilsbøll T, et al. KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:603-608
25. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912-917 (Pubitemid 23110837)
26. Mentis N, Nauck MA, Köthe L, et al. Glucose-dependent insulinotropic polypeptide (GIP) does not potentiate the antidiabetic effects of glucagonlike peptide-1 (GLP-1) in hyperglycaemic patients with type 2 diabetes mellitus (Abstract). Diabetologia 2009;52(Suppl. 1):S312
27. El-Ouaghlidi A, Rehring E, Holst JJ, et al. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007;92:4165-4171 (Pubitemid 350074727)
28. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994;43:535-539
29. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85:3575-3581
30. Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003;88:2706-2713 (Pubitemid 36724446)
31. Holst JJ. Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-69) of glicentin. Biochem J 1982;207:381-388 (Pubitemid 13138851)
32. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377
33. Polonsky KS, Licinio-Paixao J, Given BD, et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 1986;77:98-105 (Pubitemid 16101207)
34. Hovorka R, Soons PA, Young MA. ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 1996;50:253-264 (Pubitemid 26308809)
35. Hovorka R, Koukkou E, Southerden D, Powrie JK, Young MA. Measuring pre-hepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. Diabetologia 1998;41:548-554 (Pubitemid 28206825)
36. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-3723 (Pubitemid 32755966)
37. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57:678-687
38. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798-801 (Pubitemid 36831408)
39. de Heer J, Pedersen J, Orskov C, Holst JJ. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas. Diabetologia 2007;50:2135-2142 (Pubitemid 47373847)
40. Gallwitz B, Witt M, Fölsch UR, Creutzfeldt W, Schmidt WE. Binding specificity and signal transduction of receptors for glucagon-like peptide-1 (7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. J Mol Endocrinol 1993;10:259-268
41. Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Evaluation of β-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000;23:807-812 (Pubitemid 30414198)
42. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003;52:380-386 (Pubitemid 36173193)
43. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115-121 (Pubitemid 36773875)
44. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-1304
45. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996;81:327-332
46. Meier JJ, Goetze O, Anstipp J, et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab 2004;286:E621-E625 (Pubitemid 38374960)
47. Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens postprandial hyperglycemia in type 2 diabetes. Diabetes 2009;58:1342-1349
48. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1126-1131
49. Gault VA, Flatt PR, O'Harte FP. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 2003;308:207-213 (Pubitemid 36937167)
50. Irwin N, Green BD, Mooney MH, et al. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J Pharmacol Exp Ther 2005;314:1187-1194
51. Irwin N, Green BD, Gault VA, Harriot P, O'Harte FP, Flatt PR. Stable agonist of glucose-dependent insulinotropic polypeptide (GIP) restores pancreatic beta cell glucose responsiveness but not glucose intolerance in aging mice. Exp Gerontol 2006;41:151-156 (Pubitemid 43165688)
52. Irwin N, Hunter K, Frizzell N, Flatt PR. Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice. Regul Pept 2009;153:70-76
53. Suzuki S, Kawai K, Ohashi S, Mukai H, Murayama Y, Yamashita K. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas. Diabetes 1990;39:1320-1325
54. Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009;52:199-207